ANALYSIS OF RARE CELL-ENRICHED SAMPLES

• US 20080124721A1
• Filed: 06/13/2007
• Published: 05/29/2008
• Est. Priority Date: 06/14/2006
• Status: Abandoned Application

• Current Assignee: Gpb Scientific, LLC, Mehmet Toner
• Original Assignee: Gpb Scientific, LLC
• Inventors: Toner, Mehmet, Kapur, Ravi, Wang, Zihua, Fuchs, Martin
• Application Number:
  US11/762,750
• Publication Number:
  US 20080124721A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: G01N 1/405 by adsorption or absorption
• CPC Class Codes: G01N 2015/1006 for cytology
• CPC Class Codes: G01N 2015/1029 Particle size
• CPC Class Codes: G01N 2800/385 Congenital anomalies
• CPC Class Codes: G01N 33/5005 involving human or animal cells immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025
• CPC Class Codes: G01N 33/5091 for testing the pathological state of an organism
• CPC Class Codes: G01N 33/57484 involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Abstract

The present invention relates to methods for detecting, enriching, and analyzing rare cells that are present in the blood, e.g., epithelial cells. The invention further features methods of analyzing rare cell(s) to determine the presence of an abnormality, disease or condition in a subject by analyzing a cellular sample from the subject.

Claims

1. A method for detecting cancer in a subject comprising:

enriching a sample from said subject for rare cells by flowing said sample through an array of obstacles coated with antibodies that specifically bind to one or more cell populations in said sample to obtain a rare cell-enriched sample, wherein said rare cells in said sample are in a concentration of less than 1 in 100,000 cells prior to said enrichment, and

detecting the presence or absence of a rare cell nucleic acid in said rare cell-enriched sample, wherein the presence of said rare cell nucleic acid in said rare cell-enriched sample indicates the presence of said cancer in said subject.

2. The method of claim 1, wherein said array of obstacles comprises about 5,000 to about 100,000 obstacles.

3. The method of claim 1, wherein said rare cell-enriched sample is not eluted from said array prior to said detecting.

4. The method of claim 1, wherein outflow from said array occurs in a single direction.

5. The method of claim 1, wherein said array of obstacles comprises 20-500 rows.

6. The method of claim 5, wherein said rows have a continuous offset.

7. The method of claim 1, wherein said sample is a blood sample.

8. The method of claim 1, wherein said sample is treated with a stabilizer, a preservative, or a fixant prior to said enriching.

9. The method of claim 1, wherein said rare cells comprise circulating tumor cells, epithelial cells, endothelial cells, or progenitor stem cells.

10. The method of claim 9, wherein said rare cells comprise epithelial cells.

11. The method of claim 9, wherein said detecting comprises detecting the expression of a gene identified in FIG. 5.

12. The method of claim 11, further comprising detecting the presence or absence of a mutation in said gene.

13. The method of claim 11, wherein a level of expression of said gene is determined.

14. The method of claim 11, wherein said gene is EGFR, EGF, EpCAM, MUC-1, HER-2, or Claudin-7.

15. The method of claim 14, wherein said gene is EpCAM.

16. The method of claim 14, wherein said gene is EGFR or EGF.

17. The method of claim 1, wherein said enriching step comprises flowing said sample or a fraction thereof through one or more magnetic fields that selectively retain paramagnetic components.

18. The method of claim 1, further comprising (i) applying hyperbaric pressure to said sample or a fraction thereof prior to said enriching to selectively eject nuclei of said rare cells;

or (ii) applying hyperbaric pressure to said enriched sample or a fraction thereof to selectively eject nuclei of said rare cells.

19. The method of claim 1, wherein said antibodies comprise an anti-EpCAM antibody, an anti-E-cadherin antibody, or an anti-Muc-1 antibody.

20. The method of claim 19, wherein said antibodies comprise an anti-EpCAM antibody.

21. The method of claim 19, wherein said antibodies comprise at least two antibodies from said anti-EpCAM antibody, said anti-E-cadherin antibody, or said anti-Muc-1 antibody.

22. The method of claim 1, wherein said antibodies comprise an anti-CD71 antibody, anti-CD235a antibody, anti-CD36 antibody, an anti-selectin antibody, an anti-CD45 antibody, or an anti-GPA antibody.

23. The method of claim 1, comprising performing said enriching and detecting on samples obtained at two or more time points.

24. The method of claim 1, further comprising flowing said sample or said enriched sample through an array of obstacles that selectively directs cells larger than a predetermined size in to a first outlet and cells equal to or smaller than said predetermined size to a second outlet.

25. The method of claim 1, wherein said predetermined size is about 2 to about 10 μ

m.

26. A method for detecting cancer in a subject comprising:

(i) enriching a sample from said subject for rare cells by flowing said sample through an array of obstacles that selectively directs cells smaller than a predetermined size to a first outlet and cells equal to or larger than said predetermined size to a second outlet to obtain a first rare cell-enriched sample, wherein said rare cells in said sample are in a concentration of less than 1 in 100,000 cells;

(ii) flowing said first rare cell-enriched sample through an array of obstacles coated with antibodies that specifically bind to one or more cell populations in said sample to obtain a second rare cell-enriched sample; and

(iii) detecting the presence or absence of a rare cell nucleic acid in said second rare-cell enriched sample, wherein the presence of said rare cell nucleic acid in said second rare-cell enriched sample indicates the presence of said cancer in said subject.

27. The method of claim 26, wherein said predetermined size is about the size of a red blood cell, a white blood cell, a circulating tumor cell, an epithelial cell, an endothelial cell, or a progenitor stem cell.

28. The method of claim 26, wherein said predetermined size is about 1 to about 10 μ

m.

29. The method of claim 26, wherein said rare cell nucleic acid is from an epithelial cell.

30. The method of claim 26, wherein said rare cell nucleic acid is EGFR, EGF, EpCAM, MUC-1, HER-2, or Claudin-7.

31. The method of claim 30, wherein said rare cell nucleic acid is EpCAM.

32. The method of claim 30, wherein said rare cell nucleic acid is EGFR or EGF.

33. The method of claim 26, wherein said cancer is breast cancer, lung cancer, or prostate cancer.

34. A method for determining cancer treatment efficacy in a patient, comprising:

(i) enriching, for epithelial cells, each of a plurality of blood samples from said patient by flowing each blood sample in said plurality through an array of obstacles coated with one or more antibodies that specifically bind to epithelial cells to obtain a plurality of epithelial cell-enriched blood samples, wherein said plurality of blood samples was generated by obtaining a blood sample from said patient at a series of time points during said cancer treatment, and said series of time points includes at least a first time point at the beginning of said treatment and at least two points subsequent to said first time point;

(ii) quantifying in each epithelial-cell enriched sample of said plurality, the expression level of at least one gene expressed in epithelial cells and not expressed in other cells present in blood, to obtain a temporal expression profile for said at least one gene in said plurality of epithelial cell-enriched blood samples; and

(iii) determining that said cancer treatment is efficacious if said temporal expression profile indicates a decreasing trend of expression levels for said at least one gene.

35. The method of claim 34, wherein said expression level is an mRNA expression level.

36. The method of claim 34, wherein said antibodies comprise an anti-EpCAM antibody, an anti-E-cadherin antibody, or an anti-Muc-1 antibody.

37. The method of claim 36, wherein said antibodies comprise an anti-EpCAM antibody.

38. The method of claim 34, wherein said detecting comprises detecting the expression of a gene identified in FIG. 5.

39. The method of claim 38, wherein said gene is EGFR, EGF, EpCAM, MUC-1, HER-2, or Claudin-7.

40. The method of claim 38, wherein said gene is EpCAM.

41. The method of claim 38, wherein said gene is EGFR.

42. The method of claim 41, further comprising detecting the presence of a mutation in said EGFR gene.

43. A kit for detecting cancer cells in a subject, comprising a device comprising an array of obstacles coated with antibodies that specifically bind to one or more cell populations and a set of reagents for detecting the expression of a gene identified in FIG. 5.

44. The kit of claim 43, wherein said gene is EGFR, EGF, EpCAM, MUC-1, HER-2, or Claudin-7.

45. The kit of claim 43, wherein said gene is EpCAM.

46. The kit of claim 43, wherein said gene is EGFR.

47. The kit of claim 43, wherein said expression of a gene is mRNA expression of said gene.